Trials / Completed
CompletedNCT00725439
An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne
An Open Label Pilot Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment of Moderate to Severe Facial Acne
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Stiefel, a GSK Company · Industry
- Sex
- Male
- Age
- 16 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is looking at a new oral drug to treat acne. All patients in the study will get active drug, there is no placebo arm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talarozole | Oral Dose 1.0 mg once daily |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2005-07-01
- Completion
- 2007-12-01
- First posted
- 2008-07-30
- Last updated
- 2011-09-26
Locations
3 sites across 2 countries: Belgium, Netherlands
Source: ClinicalTrials.gov record NCT00725439. Inclusion in this directory is not an endorsement.